Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill, Daniel J. Drucker
Endocrine Reviews (2014) Vol. 35, Iss. 6, pp. 992-1019
Open Access | Times Cited: 528

Showing 1-25 of 528 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 929
Adipokines in health and disease
Mathias Faßhauer, Matthias Blüher
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 7, pp. 461-470
Closed Access | Times Cited: 923
Targeting adipose tissue in the treatment of obesity-associated diabetes
Christine M. Kusminski, Perry E. Bickel, Philipp E. Scherer
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 9, pp. 639-660
Closed Access | Times Cited: 612
Fluorogenic probes for disease-relevant enzymes
Junji Zhang, Xianzhi Chai, Xiao‐Peng He, et al.
Chemical Society Reviews (2018) Vol. 48, Iss. 2, pp. 683-722
Closed Access | Times Cited: 537
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 15-30
Open Access | Times Cited: 522
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 498
Anxiety, Depression, and the Microbiome: A Role for Gut Peptides
Gilliard Lach, Harriët Schellekens, Timothy G. Dinan, et al.
Neurotherapeutics (2017) Vol. 15, Iss. 1, pp. 36-59
Open Access | Times Cited: 489
Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19)
Yue Zhou, Jingwei Chi, Wenshan Lv, et al.
Diabetes/Metabolism Research and Reviews (2020) Vol. 37, Iss. 2
Open Access | Times Cited: 469
Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications
Daniel J. Drucker
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 391
DPP4 in diabetes
Diana Röhrborn
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 387
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 329
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 313
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 642-653
Closed Access | Times Cited: 270
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Jan‐Bernd Funcke, Philipp E. Scherer
Journal of Lipid Research (2019) Vol. 60, Iss. 10, pp. 1648-1697
Open Access | Times Cited: 259
Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 251
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 215
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 209
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 196
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean, Chi Kin Wong, Jonathan E. Campbell, et al.
Endocrine Reviews (2020) Vol. 42, Iss. 2, pp. 101-132
Open Access | Times Cited: 195
Viral infiltration of pancreatic islets in patients with COVID-19
Charlotte Steenblock, Stefanie Richter, Ilona Berger, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 167
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
Konstantinos Makrilakis
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 15, pp. 2720-2720
Open Access | Times Cited: 159
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 7, pp. 413-432
Open Access | Times Cited: 147
Autoimmune pre-disease
Katja Bieber, Jennifer E. Hundt, Xinhua Yu, et al.
Autoimmunity Reviews (2022) Vol. 22, Iss. 2, pp. 103236-103236
Closed Access | Times Cited: 78
Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target
Kai Wang, Zhiwei Zhang, Jing Hang, et al.
Science (2023) Vol. 381, Iss. 6657
Open Access | Times Cited: 78
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top